Evidence overview
GHK-Cu
GHK-Cu is a copper tripeptide most heavily researched for topical skin applications (cosmetic dermatology, wound healing, hair growth). The systemic-supplementation literature - oral or injected GHK-Cu - is small and emerging. Topical evidence is more developed than systemic evidence, which is the most-practical framing for consumers considering the compound.
Most studied for
Coverage pending
PubMed coverage
Coverage pending
Safety profile
In your full report
Mechanism class
Naturally-occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva, and urine. Bound to copper,...
Study coverage
Study coverage by goal
PubMed counts for GHK-Cu grouped by the goal each study targets.
Evidence overview is temporarily unavailable for GHK-Cu.
Evidence
What the evidence covers
The terrain of the published literature, not its conclusions.
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally-occurring copper-binding tripeptide found in human plasma, saliva, and urine. The published research base concentrates heavily on topical applications: skin remodeling and cosmetic dermatology (firmness, photoaging, fine lines), wound healing in clinical contexts, hair growth (where the compound is included in some over-the-counter and prescription-adjacent hair-loss products), and burn and scar management. The systemic-supplementation literature - oral GHK-Cu or injectable GHK-Cu - is substantially smaller and more recent. Most consumer marketing for systemic use extrapolates from topical-skin and preclinical evidence.
The outcome dimensions covered most heavily in the topical literature are cosmetic skin outcomes (firmness, hydration, fine lines), wound healing in clinical and post-surgical contexts, and hair regrowth in androgenetic alopecia. Topical GHK-Cu is included in some cosmetic and dermatologic product lines and has cleared the regulatory bar for cosmetic use in many jurisdictions. The much smaller systemic-use literature covers extrapolated tendon and connective tissue applications, hair growth (oral and injectable), and broader anti-aging hypotheses, generally without the systematic-review or expert-society synthesis that would support standard consumer-supplement claims.
The defining feature of the GHK-Cu literature for systemic supplementation is the gap between topical evidence (more developed) and oral/injectable evidence (substantially smaller). Most systemic-use claims rest on extrapolation from topical and preclinical findings. Route of administration matters substantially: topical application acts locally on skin and follicle tissue, while systemic (oral or injectable) administration would have to address absorption, distribution, and metabolism in ways that the available research has not characterized in depth. Product quality and purity vary substantially across sources, particularly for injectable forms typically sold via compounding pharmacies.
Safety
Safety summary
Common adverse events, drug interactions, and special populations.
Topical GHK-Cu has a generally clean safety profile across cosmetic and dermatologic use. The most-common topical adverse effects are mild skin irritation, redness, and (rarely) allergic contact dermatitis. Systemic-supplementation safety is much less well-characterized: oral and injectable use have not been subject to the systematic safety evaluation that topical products in regulated cosmetic and pharmaceutical markets undergo. Excess copper intake is a theoretical concern with systemic supplementation, given the supplement delivers a copper-bound peptide and chronic high copper intake can cause adverse effects including gastrointestinal symptoms and (rarely) hepatic effects. People considering systemic (oral or injectable) GHK-Cu should be aware of the limited safety data and consult a clinician.
This summary is informational and not medical advice. Consult a clinician before starting or changing any supplement, especially if you take prescription medications.
Limitations
What this page doesn't answer
Where the public summary stops and the personalized report begins.
This page summarizes the GHK-Cu literature at a general level. The most-important limitation is the structural gap between topical evidence (more developed) and systemic evidence (substantially smaller): most consumer marketing for oral or injectable GHK-Cu extrapolates from topical and preclinical data. It does not address route selection (topical vs. oral vs. injectable, with very different evidence bases and use cases), product quality (which varies substantially), what dose has any meaningful clinical support, or how GHK-Cu fits with your specific situation. The personalized report cannot provide firm recommendations for systemic GHK-Cu because the underlying evidence base is not yet sufficient to support them - particularly when topical alternatives have stronger evidence for many of the same outcomes.
Personalized to you
Get a personalized GHK-Cu report
Your free first report adds the things this page doesn't: per-goal evidence breakdown, demographic-specific findings, full citation list, and a safety section tailored to your profile.
Free first report. No credit card. Cancel anytime.
Get notified when new evidence appears
We'll email you when the literature on GHK-Cu materially updates. No account required.